Skip Navigation


European Heart Journal Advance Access originally published online on August 25, 2009
European Heart Journal 2009 30(21):2558-2559; doi:10.1093/eurheartj/ehp307
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/21/2558    most recent
ehp307v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ommen, S. R.
Right arrow Articles by Gersh, B. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ommen, S. R.
Right arrow Articles by Gersh, B. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Sudden cardiac death risk in hypertrophic cardiomyopathy

Steve R. Ommen* and Bernard J. Gersh

Mayo Clinic, Rochester, MN 55905, USA

* Corresponding author. Tel: +1 507 284 8260, Fax: +1 507 266 0103, Email: ommen.steve@mayo.edu

This editorial refers to ‘Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers’{dagger}, by M. Michels et al., on page 2593 and

‘Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy’{ddagger}, by J.R. Gimeno et al., on page 2599

The first 10% of the full text of this article appears below.

It is well recognized that sudden cardiac death (SCD) is an infrequent, unpredictable, but catastrophic complication of hypertrophic cardiomyopathy (HCM)1. In population-based studies the overall SCD rate is ~1% per year among patients with a clinical diagnosis of HCM. A crucial aspect of the management of patients with HCM is an assessment of each individual patient's risk for SCD so that preventative strategies may be considered. Data on the effectiveness of any pharmacological strategy to prevent SCD are at best conflicting so that ultimately . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers
Michelle Michels, Osama I.I. Soliman, Judith Phefferkorn, Yvonne M. Hoedemaekers, Marcel J. Kofflard, Dennis Dooijes, Danielle Majoor-Krakauer, and Folkert J. Ten Cate
EHJ 2009 30: 2593-2598. [Abstract] [Full Text]  

Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy
Juan R. Gimeno, Maite Tomé-Esteban, Carla Lofiego, José Hurtado, Antonios Pantazis, Bryan Mist, Pier Lambiase, William J. McKenna, and Perry M. Elliott
EHJ 2009 30: 2599-2605. [Abstract] [Full Text]